Prescribing information

 

This site contains information for UK healthcare professionals only on Xolair and chronic spontaneous urticaria.

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1

 

*Post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.2

DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.

References

  1. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
  2. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
XSU20-C027 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]